X
skip to main content
Logo
  • February 15, 2018

    A Vancouver team led by TFRI-funded investigator Dr. David Huntsman has discovered an important therapeutic target for treating small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). This is a rare, but extremely lethal, ovarian cancer in young women with no effective treatment.

  • February 15, 2018

    A pan-Canadian TFRI team of cancer researchers has developed a predictive model for detecting early-stage lung cancer in high-risk individuals with significantly greater accuracy than other leading models. This study suggests the team’s innovative approach could be considered for use in lung cancer screening programs both in Canada and around the world.

  • February 15, 2018

    A recent study by TFRI’s cancer metabolism group suggests nuclear mTOR (a kinase) also works as a transcriptional regulator of metabolism in the proliferation of prostate cancer.

  • February 15, 2018

    A new class of compounds is generating excitement for its ability to enhance the efficacy of oncolytic viruses (OVs) and to stimulate the immune response against tumours when used in combination therapy.

  • February 15, 2018

    What if there was a way to make cancer cells more susceptible to radiation therapy without damaging healthy cells? New findings from Toronto researchers have shown ultrasound- stimulated microbubbles is a novel type of treatment that may achieve just that.

  • February 15, 2018

    While nuclear mutations are widely acknowledged as a driver of cancer tumours, the role of maternally inherited mitochondrial genome mutations has not been extensively explored – but now a paper from a prolific TFRI-funded team has suggested an important interplay between the two mutations when it comes to prostate cancer tumours.

  • February 08, 2018

    As part of its 10th anniversary celebration, TFRI presented a session titled The Marathon of Hope Lecture Series at the Canadian Cancer Research Conference(Vancouver) in November 2017 that featured four premier TFRI-funded researchers: John Dick (PM, Toronto), John Bell (OHRI, Ottawa), Stephen Lam (UBC, Vancouver) and Marco Marra, BC Cancer .

  • January 19, 2018

    The annual Terry Fox Research Institute’s Ontario Node Research Symposium took place Monday, Dec. 4, 2017 at the MaRS Discovery Centre in Toronto. Photos of the event are now posted, check out the gallery here.

  • January 03, 2018

    A new study led by TFRI-funded researchers at The Ottawa Hospital (TOH) and the University of Ottawa suggests that a combination of two immunotherapies (oncolytic viruses and checkpoint inhibitors) could be much more successful in treating breast cancer and possibly other cancers.

  • December 12, 2017

    More than 200 cancer researchers attended TFRI's 8th Annual Scientific Meeting in Vancouver on Nov. 4. Photos of the event are now posted, check out the gallery here.

  • December 07, 2017

    This was a big year for the Terry Fox Research Institute: 2017 marked our 10th anniversary. Here are two videos we created to celebrate this milestone, telling the story of TFRI's origins, and how we are achieving Terry Fox's dream of finding cures for cancer through research.

  • November 24, 2017

    For the first time in Canadian history, more than 30 pediatric cancer research and funding organizations have joined forces through Terry Fox PROFYLE, a pan-Canadian project to give children, adolescents and young adults who are out of conventional treatment options another chance to beat their cancer.

  • October 26, 2017

    The B.C. Lung Screen Trial at Vancouver General Hospital is currently recruiting 2,000 individuals from the Lower Mainland who are between 55 and 80 years of age, with at least a 30-pack-years smoking history to take part in a new research project.

  • October 18, 2017

    A pan-Canadian team of cancer researchers has developed a predictive model for detecting early-stage lung cancer in high-risk individuals with significantly greater accuracy than other leading models. This Terry Fox Research Institute study suggests the team’s innovative approach could be considered for use in lung cancer screening programs both in Canada and around the world.

  • September 06, 2017

    TFRI is pleased to announce that it will be presenting a concurrent session (D6 in program) at the upcoming Canadian Cancer Research Conference featuring talks by four outstanding Canadian investigators: Dr. John Bell (OHRI) Dr. John Dick (UHN), Dr. Stephen Lam (BC Cancer Agency), and Dr. Marco Marra (BC Cancer Agency).

Back to Top